Siena Biotech Appoints Proteome Sciences as Preferred Proteomic Services Supplier
Proteome Sciences plc is pleased to announce that it has entered into a Master Research Agreement with Siena Biotech S.p.A. under which it has been retained as preferred supplier of protein and peptide biomarker services for Siena's drug development programs.
In the first project under the MRA Proteome will apply its PS Biomarker Services™ to deliver a detailed analysis of post-translational modifications on a neurological disease-related protein. Proteome will apply proprietary sample preparation and analytical methods combined with state-of-the-art Orbitrap Velos mass spectrometry to deliver a high-density PTM map of Siena Biotech's protein target. Such maps are often used to confirm proof of disease mechanism and/or mode of action of new targeted therapeutics providing information to support go/no-go decisions in early drug development.
"Proteome Sciences plc will perform Mass Spectrometry analysis on proteins of interest to Siena Biotech" said Andrea Caricasole, Head of Pharmacology at Siena Biotech.
Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:
"I am pleased to have Siena Biotech join the growing list of international pharmaceutical companies who have confidence in PS Biomarker Services™ to deliver high quality, mission-critical data within the required time and budget. Our unique approach to protein and peptide biomarker research on latest generation mass spectrometers is increasingly recognised as adding significant value to pre-clinical and clinical research projects. In addition, using Tandem Mass Tags™ we can rapidly develop targeted mass spectrometry assays for implementation in clinical trials and routine clinical medicine. We look forward to meeting Siena Biotech's current and future requirements for high quality biomarker services through our ISO 9001:2008 accredited facility in Frankfurt, Germany."